FY2024 Earnings Forecast for Femasys Issued By HC Wainwright

Femasys Inc. (NASDAQ:FEMY) – HC Wainwright reduced their FY2024 EPS estimates for Femasys in a research report issued to clients and investors on Tuesday, November 12th. HC Wainwright analyst E. Bodnar now anticipates that the company will earn ($0.84) per share for the year, down from their previous estimate of ($0.78). HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Femasys’ current full-year earnings is ($0.79) per share. HC Wainwright also issued estimates for Femasys’ Q4 2024 earnings at ($0.22) EPS, FY2025 earnings at ($0.42) EPS, FY2026 earnings at ($0.23) EPS, FY2027 earnings at ($0.19) EPS and FY2028 earnings at ($0.04) EPS.

Separately, Chardan Capital dropped their price objective on shares of Femasys from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday.

Femasys Stock Performance

NASDAQ:FEMY opened at $0.95 on Friday. Femasys has a twelve month low of $0.73 and a twelve month high of $2.40. The company has a market capitalization of $21.82 million, a P/E ratio of -1.18 and a beta of -2.83. The company has a current ratio of 3.94, a quick ratio of 5.93 and a debt-to-equity ratio of 0.86. The firm has a 50-day moving average price of $1.16 and a two-hundred day moving average price of $1.15.

Femasys (NASDAQ:FEMY) last posted its earnings results on Tuesday, November 12th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.04). Femasys had a negative net margin of 1,435.77% and a negative return on equity of 141.49%. The firm had revenue of $0.55 million during the quarter, compared to analyst estimates of $0.40 million.

Hedge Funds Weigh In On Femasys

Several institutional investors and hedge funds have recently modified their holdings of the company. CM Management LLC boosted its holdings in shares of Femasys by 6.3% during the second quarter. CM Management LLC now owns 425,000 shares of the company’s stock worth $484,000 after purchasing an additional 25,000 shares during the last quarter. XTX Topco Ltd boosted its stake in Femasys by 123.9% in the 3rd quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock worth $36,000 after buying an additional 18,004 shares during the last quarter. Finally, Aljian Capital Management LLC purchased a new stake in Femasys in the 3rd quarter valued at about $27,000. Hedge funds and other institutional investors own 65.27% of the company’s stock.

Femasys Company Profile

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.